Cellens, Inc

Lucell Diagnostics Inc, based in Cambridge, MA, is pioneering a novel diagnostic approach known as Membrane Voltage Profiling (MVPro), which enables surgeons to assess the entire surgical margin with a single image during operations. This innovative technology aims to enhance patient outcomes by providing real-time information on whether tumor removal is complete, thereby reducing the need for extensive tissue removal and minimizing the risks associated with post-surgical treatments. The company's approach benefits not only surgeons but also pathologists, who can utilize MVPro's insights to determine which tissue samples require further examination for accurate diagnosis. By offering a cost-effective and straightforward solution, Lucell Diagnostics strives to improve care in healthcare settings that currently lack advanced diagnostic tools. Generated from the website

Boston Micromachines, based in Cambridge, MA, specializes in pioneering MEMS micro-electro-mechanical systems deformable mirrors that enable advanced optical control for researchers across various fields, including astronomy, microscopy, and laser communication. Their high-resolution deformable mirrors and versatile optical modulators empower scientific breakthroughs by providing enhanced wavefront manipulation capabilities. With a commitment to innovation in photonics applications, Boston Micromachines offers adaptive optics software and MEMS grating modulators that facilitate superior image sharpening and data throughput. Their products are designed to meet the demands of diverse industries, driving advancements in high-resolution imaging systems and laser technologies. Generated from the website

MAKScientific is a Boston-based pharmaceutical company that is dedicated to developing drugs targeting the endocannabinoid system to treat various medical disorders. With a focus on selective targeting of components such as cannabinoid receptors and enzymes, they have a growing portfolio of small molecule modulators that have shown promise in animal models of human disease. One of their advanced drug candidates, AM6545, is a peripherally restricted CB1 receptor antagonist that offers a potential new approach to managing chronic liver disease and metabolic disorders. Seeking a partner for further development and commercialization, MAKScientific has already advanced this drug candidate to the late pre-clinical stage with no adverse pre-clinical data to date.Generated from the website